Enveric Biosciences (NASDAQ:ENVB) Upgraded to Hold at Wall Street Zen

Enveric Biosciences (NASDAQ:ENVB) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Enveric Biosciences Stock Performance

Shares of ENVB stock opened at $1.28 on Friday. Enveric Biosciences has a 52-week low of $1.26 and a 52-week high of $17.64. The firm has a market capitalization of $4.71 million, a PE ratio of -0.05 and a beta of 1.11. The stock has a fifty day simple moving average of $2.51 and a two-hundred day simple moving average of $3.06.

Enveric Biosciences (NASDAQ:ENVB) last posted its quarterly earnings results on Friday, May 15th. The company reported ($1.08) EPS for the quarter.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.